David Weng

1.6k total citations
41 papers, 1.1k citations indexed

About

David Weng is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, David Weng has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Oncology and 11 papers in Immunology. Recurrent topics in David Weng's work include Immunotherapy and Immune Responses (6 papers), CAR-T cell therapy research (5 papers) and Cancer therapeutics and mechanisms (4 papers). David Weng is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), CAR-T cell therapy research (5 papers) and Cancer therapeutics and mechanisms (4 papers). David Weng collaborates with scholars based in United States, Malaysia and Switzerland. David Weng's co-authors include Nassim Usman, Peter A. Cohen, Brian J. Czerniecki, Gary K. Koski, Martin A. Graham, Alex A. Adjei, Suyu Shu, Ravi K. Amaravadi, Liaomin Peng and Russell J. Schilder and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

David Weng

41 papers receiving 1.1k citations

Peers

David Weng
Cynthia R. Giver United States
Seon-Ah Ha South Korea
Isabelle Girault France
Valeria De Giorgi United States
Brian Crain United States
Yi Zeng United States
Sebastian Boeltz Germany
Satoshi Takaki Japan
Hans-Jürgen Gober China
Andrea Worschech United States
Cynthia R. Giver United States
David Weng
Citations per year, relative to David Weng David Weng (= 1×) peers Cynthia R. Giver

Countries citing papers authored by David Weng

Since Specialization
Citations

This map shows the geographic impact of David Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Weng more than expected).

Fields of papers citing papers by David Weng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Weng. The network helps show where David Weng may publish in the future.

Co-authorship network of co-authors of David Weng

This figure shows the co-authorship network connecting the top 25 collaborators of David Weng. A scholar is included among the top collaborators of David Weng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Weng. David Weng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Eric, et al.. (2025). Patient outcomes and safety of combination biologic therapy with dupilumab. Annals of Allergy Asthma & Immunology. 135(1). 23–30.e3. 2 indexed citations
2.
3.
4.
Amaravadi, Ravi K., Russell J. Schilder, Lainie P. Martin, et al.. (2015). A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics. 14(11). 2569–2575. 101 indexed citations
5.
Meisenberg, Barry, et al.. (2015). Patient attitudes toward cancer care financial burden.. Journal of Clinical Oncology. 33(15_suppl). e17805–e17805. 1 indexed citations
6.
Amaravadi, Ravi K., Russell J. Schilder, Grace K. Dy, et al.. (2011). Abstract LB-406: Phase 1 study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors and lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Cancer Research. 71(8_Supplement). LB–406. 17 indexed citations
7.
Escobar, Pedro F., Rebecca J. Patrick, Lisa Rybicki, et al.. (2006). Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer. Annals of Surgical Oncology. 13(6). 783–787. 11 indexed citations
8.
Escobar, Pedro F., Rebecca J. Patrick, Lisa Rybicki, David Weng, & Joseph P. Crowe. (2006). The 2003 Revised TNM Staging System for Breast Cancer: Results of Stage Re-classification on Survival and Future Comparisons among Stage Groups. Annals of Surgical Oncology. 14(1). 143–147. 22 indexed citations
9.
Crowe, Joseph P., Rebecca J. Patrick, Lisa Rybicki, et al.. (2006). A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. The Breast. 15(6). 728–735. 15 indexed citations
10.
Sportès, Claude, Nicole McCarthy, Frances T. Hakim, et al.. (2005). Establishing a Platform for Immunotherapy: Clinical Outcome and Study of Immune Reconstitution after High-Dose Chemotherapy with Progenitor Cell Support in Breast Cancer Patients. Biology of Blood and Marrow Transplantation. 11(6). 472–483. 14 indexed citations
11.
Weng, David & Nassim Usman. (2001). Angiozyme: A Novel angiogenesis inhibitor. Current Oncology Reports. 3(2). 141–146. 69 indexed citations
12.
Peng, Liaomin, Jørgen Kjaergäard, Gregory E. Plautz, et al.. (2000). Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression. The Journal of Immunology. 165(10). 5738–5749. 27 indexed citations
13.
Fetsch, Patricia, et al.. (2000). Detection of circulating tumor cells and micrometastases in Stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry. Diagnostic Cytopathology. 22(5). 323–328. 27 indexed citations
14.
Cohen, Peter A., Liaomin Peng, Gregory E. Plautz, et al.. (2000). CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection. Critical Reviews in Immunology. 20(1). 40–40. 96 indexed citations
15.
Koski, Gary K., Gretchen N. Schwartz, David Weng, et al.. (1999). Calcium Mobilization in Human Myeloid Cells Results in Acquisition of Individual Dendritic Cell-Like Characteristics Through Discrete Signaling Pathways. The Journal of Immunology. 163(1). 82–92. 76 indexed citations
16.
Mishra, Lopa, Tao Cai, Ariel J. Levine, et al.. (1998). Identification of elf1, a beta-spectrin, in early mouse liver development. The International Journal of Developmental Biology. 42(2). 221–224. 21 indexed citations
17.
Weng, David, Wyndham H. Wilson, Richard F. Little, & Thomas J. Walsh. (1998). Successful Medical Management of Isolated Renal Zygomycosis: Case Report and Review. Clinical Infectious Diseases. 26(3). 601–605. 62 indexed citations
18.
Weng, David, et al.. (1993). Differential Gene Expression in Fetal Mouse Germ Cells1. Biology of Reproduction. 48(3). 564–574. 16 indexed citations
19.
Weng, David & John W. Littlefield. (1991). Loss of expression of the uvomorulin gene in compaction-defective embryonal carcinoma cells. Somatic Cell and Molecular Genetics. 17(6). 617–619. 1 indexed citations
20.
Weng, David, Richard A. Morgan, & John D. Gearhart. (1989). Estimates of mRNA abundance in the mouse blastocyst based on cDNA library analysis. Molecular Reproduction and Development. 1(4). 233–241. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cynthia R. Giver Breakdown of academic impact, for papers by Seon-Ah Ha Breakdown of academic impact, for papers by Isabelle Girault Breakdown of academic impact, for papers by Valeria De Giorgi Breakdown of academic impact, for papers by Brian Crain Breakdown of academic impact, for papers by Yi Zeng Breakdown of academic impact, for papers by Sebastian Boeltz Breakdown of academic impact, for papers by Satoshi Takaki Breakdown of academic impact, for papers by Hans-Jürgen Gober Breakdown of academic impact, for papers by Andrea Worschech
Rankless by CCL
2026